Abstract
The success of chimeric antigen receptor (CAR) Tcell therapy in solid tumors, unlike in hematologic malignancies, is limited by inadequate tumor infiltration and Tcell dysfunction and exhaustion. Regional delivery of CAR Tcells in patients with solid tumors is safe and feasible; promotes infiltration, proliferation, and trafficking; and ignites functionally persisting systemic immunity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have